Asahi Kasei Pharma America Initiates Phase 3 Clinical Trial for ART-123 in Severe Sepsis Patients With Coagulopathy

WALTHAM, Mass.--(BUSINESS WIRE)--Asahi Kasei Pharma America Corp. (AKP America) today announced the initiation of an 800-patient Phase 3 clinical trial for ART-123 (recombinant human thrombomodulin, marketed as Recomodulin® in Japan) in severe sepsis patients with coagulopathy. The Phase 3 trial follows a successful 750-patient randomized, double-blind, placebo-controlled Phase 2b study that assessed the safety and efficacy of ART-123.